Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026World Journal of CardiologyOpen Access

Novel antidiabetic therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, may improve outcomes in diabetic patients with atrial fibrillation.

View Full Paper
Ask AI
Bookmark
Share

Key result

Novel antidiabetic therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, may improve outcomes in diabetic patients with atrial fibrillation.

Authors

AKAikaterini-Eleftheria KaranikolaDTDimitris TsiachrisNANikos Argyriou

Discussion

Loading...

Member takes

Overview

Finds an interrelationship between diabetes and atrial fibrillation, indicating therapeutic advances for better outcomes.

Key Points

  • Explore the relationship between diabetes mellitus and atrial fibrillation, focusing on therapeutic advancements.
  • Investigated the pathophysiological mechanisms linking diabetes and atrial fibrillation.
  • Reviewed current management strategies for atrial fibrillation in diabetic patients.
  • Assessed the impact of novel antidiabetic therapies on atrial fibrillation outcomes.
  • Diabetes mellitus increases the risk of new-onset atrial fibrillation and worsens its prognosis.
  • Recent therapies like SGLT2 inhibitors and GLP-1 receptor agonists show promise in improving outcomes.
  • A comprehensive individualized approach is essential to reduce risks in this population.

Cite This Study

Karanikola et al. (2025) studied this question. Novel antidiabetic therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, may improve outcomes in diabetic patients with atrial fibrillation.

synapsesocial.com/papers/696128f644c2cd6c68456c8chttps://doi.org/10.4330/wjc.v17.i12.114575
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies2025
  2. 2Diabetes Mellitus and Atrial Fibrillation: Mechanistic Insights and Therapeutic Impacts of Glucose-Lowering Drugs2025
  3. 3Metabolic Remodeling and Mitochondrial Stress in Atrial Fibrillation: Mechanisms and Translational Targets2025
  4. 4Type 1 diabetes mellitus and atrial fibrillation – clinical relationships, mechanistic insights and therapeutic implications2025
  5. 5Metabolic and Inflammatory Mechanisms Driving Atrial Fibrillation2025